poisar

Stocks · News reference

Novocure and Verastem Oncology Announce Clinical Trial Collaboration for Pancreatic Cancer Treatment

Novocure and Verastem Oncology have entered into a clinical trial collaboration and supply agreement to evaluate the combination of Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem's KRAS G12D inhibitor, VS-7375.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VSTM
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

    The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.

    JNJEXELABBVAGENVSTM